Journal of Pain Management and Therapy

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Opinion Article - Journal of Pain Management and Therapy (2023) Volume 7, Issue 5

A brief report on epigenetic modifications in neurological disorders.

Ming Marica*

Department of Medicine and Aging, G. d’Annunzio University, Chieti-Pescara, Italy

*Corresponding Author:
Ming Marica
Department of Medicine and Aging
G. d’Annunzio University
Chieti-Pescara, Italy

Received:24-Aug-2023,Manuscript No. AAPMT-23-113117; Editor assigned: 28-Aug-2023, PreQC No. AAPMT-23-113117(PQ); Reviewed:11-Sept-2023, QC No. AAPMT-23-113117; Revised:16-Sept-2023, Manuscript No. AAPMT-23-113117(R); Published:22-Sept-2023, DOI: 10.35841/aapmt- 7.5.162

Citation: Marica M. A brief report on epigenetic modifications in neurological disorders. J Pain Manage Ther. 2023;7(5):162

Visit for more related articles at Journal of Pain Management and Therapy


The field of neuroscience has made significant strides in understanding the complex mechanisms underlying neurological disorders. While genetic factors have long been implicated in these conditions, emerging research has shed light on the critical role of epigenetic modifications. Epigenetics refers to heritable changes in gene expression that do not involve alterations to the underlying DNA sequence. These modifications can be influenced by environmental factors and play a crucial role in the development and progression of various neurological disorders. In this article, we will explore the intricate interplay between epigenetic modifications and neurological disorders, highlighting key findings and potential therapeutic implications.

Epigenetic modifications

Before delving into the role of epigenetic modifications in neurological disorders, it's essential to grasp the fundamental mechanisms of epigenetics. The primary epigenetic modifications include DNA methylation, histone modifications, and non-coding RNA molecules such as microRNAs[1].

DNA methylation: DNA methylation involves the addition of a methyl group (CH3) to a cytosine base within the DNA molecule, typically occurring at CpG dinucleotides. This modification can repress gene expression by preventing the binding of transcription factors and other regulatory proteins to the DNA.

Histone modifications: Histones are proteins that package DNA into a compact structure known as chromatin. Post-translational modifications to histones, such as acetylation, methylation, phosphorylation, and ubiquitination, can influence chromatin structure and gene expression. For instance, histone acetylation is associated with gene activation, while histone methylation can have both activating and repressive effects, depending on the specific modification and its location within the histone protein.

Non-coding RNAs: MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are RNA molecules that do not code for proteins but play crucial roles in gene regulation. MiRNAs can bind to messenger RNAs (mRNAs) and inhibit their translation or promote mRNA degradation, thereby regulating gene expression[2].

Epigenetic landscape in neurological disorders

Now that we have a basic understanding of epigenetic modifications, let's explore how these epigenetic changes contribute to various neurological disorders:

Alzheimer's Disease (AD): Alzheimer's disease, the most common neurodegenerative disorder, is characterized by the accumulation of amyloid-beta plaques and neurofibrillary tangles in the brain. Epigenetic modifications, particularly DNA methylation and histone acetylation, have been linked to AD pathogenesis. Studies have shown altered DNA methylation patterns in genes associated with neuroinflammation, synaptic plasticity, and amyloid metabolism. These epigenetic changes may contribute to the dysregulation of key genes involved in AD progression.

Parkinson's Disease (PD): Parkinson's disease is another neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. Epigenetic modifications, including DNA methylation and histone modifications, have been implicated in PD. Researchers have identified altered DNA methylation patterns in genes involved in mitochondrial function and oxidative stress response, both of which are critical factors in PD pathogenesis. Additionally, dysregulation of microRNAs has been associated with the aberrant expression of genes related to PD.

Autism Spectrum Disorder (ASD): Autism spectrum disorder is a complex neurodevelopmental disorder with a strong genetic component. However, recent research has highlighted the role of epigenetic modifications in ASD. DNA methylation and histone modifications in genes related to synaptic function, neurodevelopment, and neurotransmitter signaling have been found to be altered in individuals with ASD. These epigenetic changes may influence brain development and contribute to the heterogeneous nature of the disorder.

Epilepsy: Epilepsy is a neurological disorder characterized by recurrent seizures. Epigenetic modifications, particularly DNA methylation, have been implicated in epilepsy. Altered DNA methylation patterns in genes associated with ion channels, neurotransmitter receptors, and synaptic plasticity have been observed in epilepsy patients. These epigenetic changes may affect neuronal excitability and seizure susceptibility.

Huntington's Disease (HD): Huntington's disease is a genetic neurodegenerative disorder caused by a mutation in the HTT gene. While HD is primarily driven by a genetic mutation, epigenetic modifications can modulate the severity and progression of the disease. Dysregulation of histone modifications, particularly histone acetylation, has been linked to HD pathogenesis. Therapies targeting histone deacetylases (HDACs) have shown promise in preclinical studies for mitigating HD symptoms by modifying epigenetic marks[1].

Potential therapeutic implications

The growing understanding of the role of epigenetic modifications in neurological disorders has opened up new avenues for therapeutic interventions. While many challenges remain, these epigenetic-based approaches hold significant promise:

Epigenetic drugs: Several drugs that target epigenetic modifications have been developed and are being explored for their potential in treating neurological disorders. For example, DNA methyltransferase inhibitors and histone deacetylase inhibitors are being investigated for their ability to reverse aberrant epigenetic marks in neurodegenerative diseases.

Precision Medicine: The epigenetic profiles of individuals with neurological disorders can enable the development of personalized treatment strategies. Precision medicine approaches aim to tailor therapies to an individual's specific epigenetic and genetic makeup, potentially increasing treatment efficacy and minimizing side effects.

Epitranscriptomics: Epitranscriptomics is a rapidly evolving field that focuses on the chemical modifications of RNA molecules. Emerging research suggests that RNA modifications, such as N6-methyladenosine (m6A), play critical roles in neurodevelopment and neurological disorders. Targeting RNA modifications could provide novel therapeutic avenues.

Lifestyle interventions: Since epigenetic modifications can be influenced by environmental factors, lifestyle interventions such as diet, exercise, and stress reduction may have a significant impact on the epigenetic regulation of genes associated with neurological disorders. These interventions can complement pharmacological approaches and improve overall outcomes[4].

Challenges and future directions

While the potential of targeting epigenetic modifications in neurological disorders is exciting, several challenges must be addressed:

Specificity and safety: Epigenetic therapies must be highly specific to avoid unintended consequences, and their long-term safety profiles need to be thoroughly evaluated.

Biomarker development: Identifying reliable epigenetic biomarkers for early diagnosis and monitoring disease progression remains a challenge in many neurological disorders.

Ethical considerations: The ethical implications of epigenetic interventions, especially in neurodevelopmental disorders, need careful consideration.

Interindividual variability: Epigenetic modifications can vary widely among individuals, making it essential to develop personalized treatment strategies[5].


The discovery of epigenetic modifications in neurological disorders has revolutionized our understanding of these complex conditions. Epigenetics provides a bridge between genetics and the environment, offering insights into the mechanisms that underlie disease development and progression. As research in this field continues to advance, it holds the promise of more effective treatments and personalized interventions for individuals affected by neurological disorders. While challenges remain, the potential benefits of harnessing epigenetic knowledge in the fight against these disorders are truly transformative.


  1. Maiti A, Drohat AC.Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: potential implications for active demethylation of CpG sites.J Biol Chem. 2011;286(41):35334-8.
  2. Indexed at, Google Scholar, Cross Ref

  3. Villeneuve LM, Natarajan R.The role of epigenetics in the pathology of diabetic complications.Am J Physiol Renal Physiol. 2010;299(1):F14-25.
  4. Indexed at, Google Scholar, Cross Ref

  5. Shen L, Toyota M, Kondo Y, et al.Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer.Proc Natl Acad Sci. 2007;104(47):18654-9.
  6. Indexed at, Google Scholar, Cross Ref

  7. Jarmalaite S, Andrekute R, Scesnaite A, et al.Promoter hypermethylation in tumour suppressor genes and response to interleukin-2 treatment in bladder cancer: A pilot study.J Cancer Res Clin Oncol. 2010;136:847-54.
  8. Indexed at, Google Scholar, Cross Ref

  9. Jin B, Tao Q, Peng J, et al.DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to altered epigenetic modifications and aberrant expression of genes regulating development, neurogenesis and immune function.Hum Mol Genet. 2008;17(5):690-709.
  10. Indexed at, Google Scholar, Cross Ref

Get the App